×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AKRO – akero therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AKRO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
12:33 pm
akro
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
Low
Report
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
11/18
12:20 pm
akro
Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights
11/12
01:55 pm
akro
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights
11/12
01:22 pm
akro
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
Low
Report
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
11/10
06:41 pm
akro
Akero Therapeutics (AKRO): Examining Valuation After Strong Year-to-Date Share Price Gains [Yahoo! Finance]
Low
Report
Akero Therapeutics (AKRO): Examining Valuation After Strong Year-to-Date Share Price Gains [Yahoo! Finance]
11/10
12:59 pm
akro
Hepta Unveils First Multi-Omic Atlas of MASH, Linking Liver Pathway Biology to cfDNA Methylation in Blood [Yahoo! Finance]
Low
Report
Hepta Unveils First Multi-Omic Atlas of MASH, Linking Liver Pathway Biology to cfDNA Methylation in Blood [Yahoo! Finance]
11/7
07:00 am
akro
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
Low
Report
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
11/5
11:45 am
akro
Halper Sadeh LLC Encourages AKRO, CADE, FSUN Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages AKRO, CADE, FSUN Shareholders to Contact the Firm to Discuss Their Rights
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
10:42 am
akro
Form 8-K Akero Therapeutics, Inc. For: Dec 02
Low
Report
Form 8-K Akero Therapeutics, Inc. For: Dec 02
11/28
06:04 am
akro
Form 4 Akero Therapeutics, Inc. For: Nov 25 Filed by: Rolph Timothy
Low
Report
Form 4 Akero Therapeutics, Inc. For: Nov 25 Filed by: Rolph Timothy
11/26
04:04 pm
akro
Form 4 Akero Therapeutics, Inc. For: Nov 24 Filed by: Young Jonathan
Low
Report
Form 4 Akero Therapeutics, Inc. For: Nov 24 Filed by: Young Jonathan
11/24
03:48 pm
akro
Form DEFA14A Akero Therapeutics, Inc.
Low
Report
Form DEFA14A Akero Therapeutics, Inc.
11/21
06:25 pm
akro
Form 4 Akero Therapeutics, Inc. For: Nov 20 Filed by: Cheng Andrew
Low
Report
Form 4 Akero Therapeutics, Inc. For: Nov 20 Filed by: Cheng Andrew
11/19
08:05 pm
akro
Form 4 Akero Therapeutics, Inc. For: Nov 17 Filed by: Rolph Timothy
Low
Report
Form 4 Akero Therapeutics, Inc. For: Nov 17 Filed by: Rolph Timothy
11/14
12:20 pm
akro
Form SCHEDULE 13G/A Akero Therapeutics, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SCHEDULE 13G/A Akero Therapeutics, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/14
12:07 pm
akro
Form SCHEDULE 13G/A Akero Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SCHEDULE 13G/A Akero Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/30
Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001
23.4%
4/9 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 15.2%
3/16 Form 10-K Akero Therapeutics, Inc. For: Dec 31 14.7%
6/19 Form 3 Akero Therapeutics, Inc. For: Jun 19 Filed by: Cheng Andrew 13.4%
4/24 Akero Therapeutics (NASDAQ: AKRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $22.00 price target on the stock. 13.1%
6/25 Form 4 Akero Therapeutics, Inc. For: Jun 24 Filed by: Harrison Seth Loring 9.7%
12/19 Form 4 Akero Therapeutics, Inc. For: Dec 17 Filed by: Atlas Venture Fund XI, L.P. 7.6%
6/20 Form 424B4 Akero Therapeutics, Inc. 7.5%
4/13 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.5%
4/7 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
4/9 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 15.2%
3/16 Form 10-K Akero Therapeutics, Inc. For: Dec 31 14.7%
6/19 Form 3 Akero Therapeutics, Inc. For: Jun 19 Filed by: Cheng Andrew 13.4%
4/24 Akero Therapeutics (NASDAQ: AKRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $22.00 price target on the stock. 13.1%
6/25 Form 4 Akero Therapeutics, Inc. For: Jun 24 Filed by: Harrison Seth Loring 9.7%
12/19 Form 4 Akero Therapeutics, Inc. For: Dec 17 Filed by: Atlas Venture Fund XI, L.P. 7.6%
6/20 Form 424B4 Akero Therapeutics, Inc. 7.5%
4/13 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.5%
4/7 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
TOP News Decliners
3/16
Q4/2019 12/31/2019 EPS -0.550 ZacksConsensus -0.580 ActVsEst 0.030 - Beat
-31.4%
1/21 Form 4 Akero Therapeutics, Inc. For: Jan 16 Filed by: Versant Venture Capital VI, L.P. -17.4%
3/18 Akero Therapeutics (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. -14.8%
9/6 Form 8-K Akero Therapeutics, Inc. For: Sep 05 -13.8%
3/6 Form 4 Akero Therapeutics, Inc. For: Mar 04 Filed by: Adelman Robert J -9.7%
12/31 Form 4 Akero Therapeutics, Inc. For: Dec 27 Filed by: Versant Venture Capital VI, L.P. -9.5%
1/2 Form 4 Akero Therapeutics, Inc. For: Dec 31 Filed by: Atlas Venture Fund XI, L.P. -8.7%
3/31 Form 8-K Akero Therapeutics, Inc. For: Mar 31 -7.8%
12/13 Form 4 Akero Therapeutics, Inc. For: Dec 13 Filed by: Rolph Timothy -7.8%
1/14 Form 4 Akero Therapeutics, Inc. For: Jan 13 Filed by: Adelman Robert J -6.0%
1/21 Form 4 Akero Therapeutics, Inc. For: Jan 16 Filed by: Versant Venture Capital VI, L.P. -17.4%
3/18 Akero Therapeutics (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. -14.8%
9/6 Form 8-K Akero Therapeutics, Inc. For: Sep 05 -13.8%
3/6 Form 4 Akero Therapeutics, Inc. For: Mar 04 Filed by: Adelman Robert J -9.7%
12/31 Form 4 Akero Therapeutics, Inc. For: Dec 27 Filed by: Versant Venture Capital VI, L.P. -9.5%
1/2 Form 4 Akero Therapeutics, Inc. For: Dec 31 Filed by: Atlas Venture Fund XI, L.P. -8.7%
3/31 Form 8-K Akero Therapeutics, Inc. For: Mar 31 -7.8%
12/13 Form 4 Akero Therapeutics, Inc. For: Dec 13 Filed by: Rolph Timothy -7.8%
1/14 Form 4 Akero Therapeutics, Inc. For: Jan 13 Filed by: Adelman Robert J -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: